Drug Profile


Alternative Names: ABT-888; NSC-737664

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories; University of Alabama at Birmingham
  • Developer Abbott Laboratories; AbbVie; Georgetown University; Narodny onkologicky ustav; National Cancer Institute (USA); Northwestern University; University of Alabama at Birmingham
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase II/III Glioblastoma
  • Phase II Brain metastases; Colorectal cancer; Germ cell and embryonal neoplasms; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours
  • Phase I/II Small cell lung cancer
  • Phase I Lymphoma; Multiple myeloma; Prostate cancer
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 27 Sep 2017 National Cancer Institute plans a phase II trial for Myeloproliferative disorders, Acute myeloid leukaemia and Chronic myelomonocytic leukaemia (Late-stage disease) (NCT03289910)
  • 21 Sep 2017 AbbVie completes a phase II trial in Colorectal cancer (First-line therapy, Combination therapy, Metastatic disease) in USA, Australia, Austria, Belgium, Germany, Hungary, Russia, Spain and the United Kingdom (NCT02305758)
  • 29 Jun 2017 AbbVie completes a phase I trial in Solid tumours (Second-line therapy or greater, Metastatic, Unresectable) in USA (PO) (NCT01853306)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top